The explanations might be that (1) BEV could inhibit the neovascularization and induce the regression of tumor blood vessels (16), meanwhile, chemotherapy exhibited the ability of anti-cancer cytotoxicity (27), therefore, BEV plus DCC might present a better anti-tumor effect; (2) BEV might enhance the chemosensitivity of gastric cancer cells via suppressing the VEGF- phosphatidylinositol 3 kinase/protein kinase B-survivin signaling cascade (28); thus, it combined with DCC could induce favorable outcomes. The gene discussed is BIRC5; the disease is gastric cancer.